Milky Way arcs over Kitt Peak National Observatory
When you buy through links on our articles, Future and its syndication partners may earn a commission.
On a warm June evening, viewers in Arizona watched the sky burst with color from the clouds of gas and dust that help create our home galaxy, the Milky Way.
The Milky Way galaxy is around 100,000 light-years in diameter, containing our solar system and many other objects. Our solar system orbits the galaxy's center, taking about 250 million years to make one revolution.
The reason our galaxy is called "the Milky Way" is due to its milky white appearance in the night sky, which, according to Greek mythology, came from the goddess Hera.
This image was captured at Kitt Peak National Observatory near Tucson, Arizona.
Kitt Peak National Observatory, a a program of the National Science Foundation's NOIRLab, hosts the recently retired McMath-Pierce Solar Telescope. According to NOIRLab, the solar telescope honors astronomers Keith Pierce and Robert McMath.
For many decades, the McMath-Pierce telescope was the largest solar telescope in the world, standing at 110 feet tall (33 meters), with a 26-foot-diameter (8 m) platform. The telescope worked by reflecting light from a mirror down a 200-foot-long (61 m) concrete optical tunnel.
In 2017, the telescope was decommissioned, after decades of serving the scientific community. It is in the process of transitioning to the NOIRLab Windows on the Universe Center for Astronomy Outreach, according to NOIRLab.
You can read more about solar telescopes and NOIRLab's research as humans continue to study the sun.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
21 minutes ago
- Medscape
Are Disposable Vapes Hiding a Sweet Trap?
A recent study from Yale University, New Haven, Connecticut, and Duke University School of Medicine, Durham, North Carolina, found that the artificial sweetener neotame is present in many popular disposable electronic cigarettes (e-cigarettes) sold in the US, regardless of whether they contain nicotine. Neotame is several times sweeter than sugar or aspartame, and some products in European Union markets also contain it. Although the additive is considered safe in food, reliable data on its inhalation are lacking, which is a critical knowledge gap, given its prevalence in e-cigarettes. A spokesperson for the Federal Institute for Risk Assessment told Medscape Medical News , 'The Federal Institute for Risk Assessment has not yet addressed neotame in its assessments of e-cigarettes and has no information on its prevalence in e-cigarettes on the German market.' Manufacturers of tobacco and nicotine products have always relied on flavours to enhance the taste of their products and to appeal to young consumers. Sweet, fruity, and cooling additives are widely used in e-cigarettes. They not only enhance the appeal but also raise the likelihood of trials. Despite their key role, sweeteners in these products remain unregulated in both the US and Europe. Recently, neotame has received particular attention due to its unique properties. This chemical substance is 7000-13,000 times sweeter than table sugar and 35-65 times sweeter than aspartame. E-cigarette manufacturers prioritise neotame for its intense sweetness and thermal stability. It is used particularly in fruity or menthol-like 'cooling' flavours to intensify the taste and create a pleasant vaping experience. One example is the Cherry Lemonade flavour offered by the brand Tauro Vape. Study The researchers investigated which e-cigarettes available in the American market contained neotame. Their focus included the most commonly used disposable products, nicotine-free e-cigarettes, devices with synthetic nicotine analogues such as 6-methyl nicotine, and products either approved by the US Food and Drug Administration (FDA; eg, Vuse and NJOY) or submitted for approval (eg, JUUL). In most cases, neotame was not listed in the outer packaging. A total of 73 e-cigarettes sold in the US were analysed to check for the presence of neotame. These included 11 popular disposable brands, 4 nicotine-free products, 2 with synthetic nicotine analogues such as 6-methyl nicotine, all FDA-approved cartridge systems (eg, Vuse and NJOY), and two products purchased in 2021. Most packaging did not list neotame. For comparison, the team assessed a commercially available mint candy. Scientists dissolved e-liquids in methanol or water and measured the neotame using liquid chromatography-mass spectrometry. Furthermore, gas chromatography was used to detect nicotine, menthol, and synthetic cooling agents similar to menthol but without its typical taste, such as WS-3 and WS-23. Neotame and Toxicology Neotame was detected in 57 of the 73 e-cigarette samples (78%). The average concentration was 1.75 µg/mg of liquid, which is approximately 4.6 times higher than the neotame concentration in a strongly flavoured mint candy used as a comparison product. Neotame was found in all tested disposable products, all nicotine-free e-cigarettes, and all devices containing the nicotine analogue 6-methyl nicotine. In contrast, neotame was not detected in any of the FDA-approved cartridges, such as those from Vuse, NJOY, or any JUUL device. Two of the four e-cigarettes purchased in 2021 suggested that neotame has been increasingly established in e-cigarettes for several years. Devices with 6-methyl nicotine showed particularly high levels (average 2.69 µg/mg, range up to 18.3 µg/mg). The study indicated that neotame is deliberately used to optimise flavour, thus making e-cigarettes more appealing to adolescents and young adults. Previous research has shown that sweetening and cooling additives, such as sucralose or menthol, can significantly enhance the appeal and addictive potential of e-cigarettes. However, some crucial questions remain. 'We don't even know exactly how much of the neotame in the liquids ends up in the aerosol of an e-cig,' said Hanno C. Erythropel, PhD, lead author and research scientist at the Department of Chemical and Environmental Engineering, Yale University. 'And how much of that neotame actually reaches the sweet taste receptors to produce a sweet sensation? These are complex questions influenced by the type of e-cigarette, the power output of the device, the design of the device, and the user's puffing behaviour — to name just a few factors.' Heat during evaporation could produce chemical degradation products whose effects on the lungs, immune system, or central nervous system have not yet been studied. The relative heat stability of neotame compared with that of other sweeteners likely explains its use by manufacturers and poses a potential risk to consumers. Regulation Push In light of these findings, researchers have advocated the stricter control of sweetening additives in e-cigarettes. Disposable products, popular among youth and often containing high-potency sweeteners such as neotame, are of particular concern. From a scientific perspective, this is concerning, as even nicotine-free versions could have a significant addictive potential due to their appealing taste. Therefore, researchers urge comprehensive studies on the toxicological effects and abuse potential of these substances. Only on this basis can a decision be made as to whether neotames should be more strictly regulated or banned in the future.
Yahoo
33 minutes ago
- Yahoo
Researchers Discover Drugs Like Ozempic Aren't as Effective Outside of Clinical Trials
Unless you've been living under a rock, you've probably heard the buzz about weight-loss drugs like Ozempic. Some people think they're a positive scientific breakthrough that can help folks with obesity; others are concerned about their side effects. No matter where you stand, you won't stop hearing about them any time soon. They're becoming a more common treatment for weight loss for everyone from celebrities to your neighbor down the street. But according to a new study from the Cleveland Clinic, semaglutides and tirzepatide—two of the most popular GLP-1 drugs—might not be as effective as scientists originally though, particularly when they're used outside research settings. The study, published in the Obesity Journal, found that people on GLP-1 medications tend to lose less weight outside of clinical trials, mostly because they don't stay on the drugs as long or use lower maintenance doses than those prescribed in research settings. 'Our study shows that patients treated for obesity with semaglutide or trizepatide lost less weight on average in a regular clinical setting compared to what is observed in randomized clinical trials," said lead author of the study Hamlet Gasoyan, Ph.D. "According to our data, this could be explained by higher rates of discontinuation and lower maintenance dosages used in clinical practice, compared to randomized clinical trial settings.' For the study, researchers looked at almost 8,000 adults with clinically-severe obesity, including over 1,300 with prediabetes. Between 2021 and 2023, all participants took either semaglutide or tirzepatide. Researchers tracked how long participants stayed on the medications as well as how much weight they 2024, the researchers broke the participants into two groups: those who discontinued treatment early (within three months of starting) or late (between three and 12 months of starting). Turns out, a lot of people didn't stick with the medication. More than 20 percent of participants stopped early, and another 32 percent stopped within a year. On top of that, over 80 percent of participants were taking lower-than-recommended maintenance doses. As you might've guessed, the longer people stayed on the drugs, the better the results. Those who ditched early lost just 3.6 percent of their body weight, while those who hung on a bit longer dropped about 6.8 percent in a year. But the real transformation came from patients who stuck with it—they lost around 11.9 percent. And when they combined that consistency with higher maintenance doses? Weight loss jumped to 13.7 percent with semaglutide and a hefty 18 percent with tirzepatide. Researchers didn't just look at weight loss either—they also tracked blood sugar levels in people who had prediabetes at the start of the study. And just like with weight, sticking with the meds for a longer period of time made a big difference. Only 33 percent of people who quit early saw their blood sugar return to normal. That went up to 41 percent for those who stayed on a bit longer. But for the people who stuck with treatment? Nearly 68 percent hit healthy blood sugar levels. 'Our findings about the real-world use patterns of these medications and associated clinical outcomes could inform the decisions of healthcare providers and their patients on the role of treatment discontinuation and maintenance dosage in achieving clinically meaningful weight reductions,' said Gasoyan. Researchers Discover Drugs Like Ozempic Aren't as Effective Outside of Clinical Trials first appeared on Men's Journal on Jun 17, 2025
Fox News
36 minutes ago
- Fox News
The Quiz #440 - It's All Greek To Me
Which is the only planet in our solar system not named after a god? Play. Share. Listen with Host of the Kennedy Saves The World podcast, Kennedy.
